Editas Medicine Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:N/A
Industry:Biotech
Founded:2013
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Editas Medicine's estimated annual revenue is currently $25.1M per year.
  • Editas Medicine received $50.0M in venture funding in December 2017.
  • Editas Medicine's estimated revenue per employee is $155,000

Employee Data

  • Editas Medicine has 162 Employees.
  • Editas Medicine grew their employee count by 5% last year.
  • Editas Medicine currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$8.7M56-12%N/A-N/A
#2
$8.7M5660%N/A-N/A
#3
$16.4M10614%N/A-N/A
#4
$89.4M577N/AN/A-N/A
#5
$116.9M754N/AN/A-N/A
#6
N/A220N/AN/A-N/A
#7
$15.3M99-17%N/A-N/A
#8
N/A94N/AN/A-N/A
#9
$54.6M352N/AN/A-N/A
#10
$17.2M1119%N/A-N/A
Missing a competitor? Contribute!?
Submit

Unlocking the Promise of Genome Editing to Deliver Life-Changing Medicines. As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

162

Number of Employees

$25.1M

Revenue (est)

1

Current Jobs

5%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Editas Medicine News

09/03/2019 - 2 stocks that intend to just keep winning: Editas Medicine ...

The recent performance of Editas Medicine (NASDAQ:EDIT) stock in the market spoke loud and clear to investors as EDIT saw more than ...

08/29/2019 - Editas Medicine to Participate in Upcoming Investor ...

CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today ...

09/03/2019 - Fishtailing Stocks: Editas Medicine ,(NASDAQ: EDIT)

On Friday the shares-rate of the Company Editas Medicine, EDIT Stock exchange NASDAQ, is an exciting player in the Medical.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$16.5M162N/AN/A-N/A
#2
$52.7M16211%N/A-N/A
#3
$23.5M16215%N/A-N/A
#4
N/A163N/AN/A-N/A
#5
N/A163N/AN/A-N/A

Editas Medicine Funding

DateAmountRoundLead InvestorsReference
2017-12-07$50.0MUndisclosedMorgan StanleyArticle

Editas Medicine Executive Hires

DateNameTitleReference
2015-04-28Vic MyerChief Technology OfficerArticle
2015-07-02Andrew HackCFOArticle
2016-01-06Timothy D. HuntSVP Corporate AffairsArticle
2018-03-30James MullenChairmanArticle